omniture
恒瑞医药

Latest News

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and ...

2026-05-12 12:27 3132

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter...

2026-04-22 17:40 4049

Hengrui Pharma Announces Strong 2025 Annual Results

SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) an...

2026-03-26 08:52 4724

Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative...

2025-09-24 19:45 2940